f5 Therapeutics

f5 Therapeutics is a private pharmaceutical company dedicated to developing "first-class" small molecules for the treatment of diseases with significant unmet medical needs. f5 Therapeutics continues to advance targeted protein degradation, transforming the landscape of drug discovery by leveraging the cell's normal protein regulation system to remove disease-causing proteins that traditional methods cannot target. The NExMods™ platform (Neosubstrate Expression Modulators) represents a novel "molecular glue" approach, capable of delivering impactful drugs for patients across various therapeutic areas, including oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration.